If You Invested $100 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 1.73% on an annualized basis producing an average annual return of 14.21%. Currently, Thermo Fisher Scientific has a marketread more...
Benzinga
More News
Here's How Innovation Fuels Globus Medical's Growth Momentum
GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.
Zacks
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
ICLR looks cheap at 14.7x forward EPS versus peers, but 2026 guidance calls for lower revenue/EPS and a weak margin starting point.
Zacks
ICLR Earnings Reset: What the Accounting Probe Changed
ICON plc details an accounting restatement, flags control weaknesses, and frames 2026 as a reset year amid mix-driven earnings swings.
Zacks
TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.
Zacks
The Zacks Analyst Blog Highlights Microsoft, Dell, Thermo Fisher,Village Super Market and Comstock
MSFT is benefiting from AI momentum, Copilot adoption and accelerating Azure growth, even as capacity constraints persist.
Zacks
Top Analyst Reports for Microsoft, Dell & Thermo Fisher
Microsoft, Dell and Thermo Fisher lead today's analyst picks as AI demand, cloud growth and biotech expansion shape outlooks and key risks.
Zacks
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.